Key result
Upfront lipid-lowering combination therapy is strongly advocated over a stepwise approach to overcome therapeutic inertia, rapidly achieve LDL-C goals, and reduce cardiovascular events in patients with ASCVD.
Upfront lipid-lowering combination therapy is strongly advocated over a stepwise approach to rapidly and effectively achieve LDL-C goals and reduce cardiovascular risk in high-risk ASCVD patients.
Recent data clearly show that we are extremely ineffective in the use of lipid-lowering therapy (LLT). Furthermore, the problem seems to be the most serious in the group of patients at very high and extremely high-risk – the patients who stand to benefit most from effective therapy.
No takes yet. Share an insight, caveat, or question.
Banach et al. (2022) conducted an editorial in Atherosclerotic cardiovascular disease (ASCVD) and dyslipidemia. Upfront lipid-lowering combination therapy vs. Stepwise lipid-lowering therapy or statin monotherapy was evaluated. Upfront lipid-lowering combination therapy is strongly advocated over a stepwise approach to overcome therapeutic inertia, rapidly achieve LDL-C goals, and reduce cardiovascular events in patients with ASCVD.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: